PL2539366T3 - Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiach - Google Patents
Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiachInfo
- Publication number
- PL2539366T3 PL2539366T3 PL11713058T PL11713058T PL2539366T3 PL 2539366 T3 PL2539366 T3 PL 2539366T3 PL 11713058 T PL11713058 T PL 11713058T PL 11713058 T PL11713058 T PL 11713058T PL 2539366 T3 PL2539366 T3 PL 2539366T3
- Authority
- PL
- Poland
- Prior art keywords
- protofibril
- synucleinopathies
- dementia
- parkinson
- alpha
- Prior art date
Links
- 206010067889 Dementia with Lewy bodies Diseases 0.000 title 1
- 201000002832 Lewy body dementia Diseases 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 208000032859 Synucleinopathies Diseases 0.000 title 1
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30863810P | 2010-02-26 | 2010-02-26 | |
| US40626010P | 2010-10-25 | 2010-10-25 | |
| EP11713058.3A EP2539366B1 (en) | 2010-02-26 | 2011-02-25 | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| PCT/IB2011/050826 WO2011104696A1 (en) | 2010-02-26 | 2011-02-25 | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2539366T3 true PL2539366T3 (pl) | 2018-06-29 |
Family
ID=44227520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11713058T PL2539366T3 (pl) | 2010-02-26 | 2011-02-25 | Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiach |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8632776B2 (no) |
| EP (1) | EP2539366B1 (no) |
| JP (1) | JP5894939B2 (no) |
| CN (3) | CN110655573B (no) |
| AU (1) | AU2011219414B2 (no) |
| CA (1) | CA2789963C (no) |
| CY (1) | CY1120014T1 (no) |
| DK (1) | DK2539366T3 (no) |
| ES (1) | ES2661925T3 (no) |
| HR (1) | HRP20180230T8 (no) |
| HU (1) | HUE038313T2 (no) |
| LT (1) | LT2539366T (no) |
| NO (1) | NO2539366T3 (no) |
| PL (1) | PL2539366T3 (no) |
| PT (1) | PT2539366T (no) |
| RS (1) | RS57029B1 (no) |
| RU (1) | RU2555526C2 (no) |
| SI (1) | SI2539366T1 (no) |
| SM (1) | SMT201800044T1 (no) |
| WO (1) | WO2011104696A1 (no) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3470079A1 (en) | 2008-04-29 | 2019-04-17 | BioArctic AB | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| SG10201700735PA (en) * | 2012-01-20 | 2017-02-27 | Genzyme Corp | Anti-cxcr3 antibodies |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| RU2697098C1 (ru) | 2013-11-21 | 2019-08-12 | Ф.Хоффманн-Ля Рош Аг | Антитела к альфа-синуклеину и способы применения |
| WO2016005466A2 (en) * | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| WO2016040905A1 (en) * | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded alpha synuclein protein |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| US10494425B2 (en) * | 2015-02-24 | 2019-12-03 | Rpeptide, Llc | Anti-amyloid-beta antibodies |
| EP3091087A1 (en) | 2015-05-08 | 2016-11-09 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts |
| GB201512203D0 (en) * | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| CA2991856A1 (en) | 2015-07-21 | 2017-01-26 | Bioarctic Neuroscience Ab | Method for treatment of traumatic brain injury targeting aggregated peptides |
| CN108350052A (zh) | 2015-11-09 | 2018-07-31 | 英属哥伦比亚大学 | 淀粉样蛋白β中间区域中的表位及其构象选择性抗体 |
| EP3374379A4 (en) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES |
| JP7452829B2 (ja) | 2015-11-09 | 2024-03-19 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータのエピトープおよびそれに対する抗体 |
| MY191649A (en) | 2016-03-04 | 2022-07-05 | Jn Biosciences Llc | Antibodies to tigit |
| WO2017207739A1 (en) * | 2016-06-02 | 2017-12-07 | Medimmune Limited | Antibodies to alpha-synuclein and uses thereof |
| CN109476728A (zh) * | 2016-07-14 | 2019-03-15 | 生命北极公司 | 脑部递送蛋白 |
| WO2018014126A1 (en) | 2016-07-18 | 2018-01-25 | The University Of British Columbia | Antibodies to amyloid beta |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| CA3043651A1 (en) | 2016-11-15 | 2018-05-24 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| MA47019A (fr) | 2016-12-16 | 2021-04-21 | H Lundbeck As | Agents, utilisations et procédés |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| CA3049110A1 (en) * | 2017-01-06 | 2018-07-12 | Abl Bio Inc. | Anti-.alpha.-syn antibody and use thereof |
| EP3583124A1 (en) * | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| AU2018255489B2 (en) * | 2017-04-21 | 2024-06-13 | Implicit Bioscience Limited | CD 14 antagonist antibodies for treating neurodegenerative diseases |
| WO2018204352A1 (en) | 2017-05-01 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| WO2018213440A1 (en) | 2017-05-16 | 2018-11-22 | Amprion, Inc. | Detection of misfolded tau protein |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| KR102826089B1 (ko) * | 2017-08-02 | 2025-06-30 | 스트레스마크 바이오사이언시즈 인코퍼레이티드 | 활성 알파 시누클레인에 결합하는 항체 |
| WO2019040617A1 (en) * | 2017-08-23 | 2019-02-28 | The Trustees Of The University Of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME |
| RU2657763C1 (ru) * | 2017-09-12 | 2018-06-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики болезни паркинсона |
| MX2020004674A (es) * | 2017-11-17 | 2020-08-13 | Abl Bio Inc | Anticuerpos contra alfa-sinucleina y usos de los mismos. |
| WO2019117685A2 (ko) | 2017-12-14 | 2019-06-20 | 에이비엘바이오 주식회사 | 항-igf1r 항체 및 그 용도 |
| GB201720970D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| EP3728567B1 (en) | 2017-12-19 | 2023-07-05 | Chase Therapeutics Corporation | Method for assessing a synucleinopathy |
| ES2898929T3 (es) * | 2017-12-21 | 2022-03-09 | H Lundbeck As | Diagnóstico y tratamiento de alfa-sinucleinopatías |
| CN109957547A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| CN109957546A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| EP3773692A4 (en) * | 2018-04-04 | 2022-03-16 | University of Florida Research Foundation, Inc. | SUBSTANCES AND METHODS FOR THE TREATMENT OF LEWY BODY DISORDERS |
| US20200017596A1 (en) * | 2018-05-10 | 2020-01-16 | Abvision, Inc. | Monoclonal antibodies activating cd40 and uses thereof |
| WO2020009482A1 (ko) * | 2018-07-03 | 2020-01-09 | 에이비엘바이오 주식회사 | 항 알파-시누클레인 항체 및 그 용도 |
| KR20210039402A (ko) | 2018-07-24 | 2021-04-09 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 알츠하이머병의 치료 및 예방 방법 |
| CA3111907A1 (en) * | 2018-10-19 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
| CN113195538B (zh) * | 2018-12-12 | 2023-03-14 | 上海药明生物技术有限公司 | 抗tim-3抗体及其用途 |
| RU2703430C1 (ru) * | 2018-12-13 | 2019-10-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| US20220194997A1 (en) * | 2019-03-28 | 2022-06-23 | The Chinese University Of Hong Kong | Sumo peptides for treating neurodegenerative diseases |
| EP3963047A4 (en) * | 2019-04-30 | 2023-06-21 | Chase Therapeutics Corporation | ALPHA SYNUCLEIN ASSAYS |
| WO2021041573A2 (en) * | 2019-08-27 | 2021-03-04 | The Johns Hopkins University | Biomarkers for neurodegenerative disorders |
| KR20220163936A (ko) | 2019-12-31 | 2022-12-12 | 체이스 테라퓨틱스 코포레이션 | 신경퇴행성 병태의 바이오마커로서 키나제 |
| CN111171152B (zh) * | 2020-01-15 | 2023-04-18 | 吉林医药学院 | Pcsk9抗体及其制备方法和应用 |
| NL2025332B1 (en) | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| MX2022015157A (es) | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Anticuerpos para tigit. |
| CN115803341A (zh) | 2020-06-26 | 2023-03-14 | 生命北极公司 | 结合α-突触核蛋白原纤维的抗体 |
| US20230365665A1 (en) | 2020-09-17 | 2023-11-16 | Qatar Foundation For Education, Science And Community Development | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES |
| EP4367516A1 (en) | 2021-07-09 | 2024-05-15 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| US20240352109A1 (en) | 2021-08-30 | 2024-10-24 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| MX2024009492A (es) | 2022-02-02 | 2024-08-09 | Eisai R&D Man Co Ltd | Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181). |
| CN117430686B (zh) * | 2022-07-22 | 2025-07-01 | 深圳市安群生物工程有限公司 | α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用 |
| CN116589567B (zh) * | 2022-11-30 | 2024-03-19 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
| WO2025245381A1 (en) | 2024-05-23 | 2025-11-27 | The Trustrees Of Dartmouth College | Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9911291A (pt) | 1998-07-03 | 2001-12-04 | Innogenetics Nv | Diagnóstico diferencial de neurodegeneração |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| WO2002003911A2 (en) | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US20060018918A1 (en) | 2000-12-27 | 2006-01-26 | Board Of Regents, The University Of Texas System | Production of stabilized conformational isomers of disease associated proteins |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| CN1886426A (zh) * | 2003-11-07 | 2006-12-27 | 伊姆尼斯公司 | 结合白细胞介素－4受体的抗体 |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| WO2005108423A1 (en) | 2004-05-11 | 2005-11-17 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US7553639B2 (en) | 2006-01-31 | 2009-06-30 | Elan Pharma International Limited | Alpha-synuclein kinase |
| NO347079B1 (no) | 2006-03-23 | 2023-05-08 | Bioarctic Neuroscience Ab | Forbedrede protofibrilselektive antistoffer og anvendelse derav |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CN101161245B (zh) * | 2007-11-29 | 2011-11-09 | 首都医科大学宣武医院 | 二苯乙烯苷及其衍生物抑制突触核蛋白过度表达的用途 |
| EP3470079A1 (en) | 2008-04-29 | 2019-04-17 | BioArctic AB | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
| PT2448968T (pt) | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
-
2011
- 2011-02-25 JP JP2012554464A patent/JP5894939B2/ja active Active
- 2011-02-25 CN CN201910950804.0A patent/CN110655573B/zh active Active
- 2011-02-25 CN CN201610801424.7A patent/CN106397588B/zh active Active
- 2011-02-25 SI SI201131419T patent/SI2539366T1/en unknown
- 2011-02-25 RS RS20180129A patent/RS57029B1/sr unknown
- 2011-02-25 ES ES11713058.3T patent/ES2661925T3/es active Active
- 2011-02-25 HR HRP20180230TT patent/HRP20180230T8/hr unknown
- 2011-02-25 SM SM20180044T patent/SMT201800044T1/it unknown
- 2011-02-25 PL PL11713058T patent/PL2539366T3/pl unknown
- 2011-02-25 PT PT117130583T patent/PT2539366T/pt unknown
- 2011-02-25 HU HUE11713058A patent/HUE038313T2/hu unknown
- 2011-02-25 US US13/578,710 patent/US8632776B2/en active Active
- 2011-02-25 NO NO11713058A patent/NO2539366T3/no unknown
- 2011-02-25 LT LTEP11713058.3T patent/LT2539366T/lt unknown
- 2011-02-25 CN CN201180011363.XA patent/CN102869680B/zh active Active
- 2011-02-25 AU AU2011219414A patent/AU2011219414B2/en active Active
- 2011-02-25 DK DK11713058.3T patent/DK2539366T3/en active
- 2011-02-25 WO PCT/IB2011/050826 patent/WO2011104696A1/en not_active Ceased
- 2011-02-25 CA CA2789963A patent/CA2789963C/en active Active
- 2011-02-25 RU RU2012140954/10A patent/RU2555526C2/ru active
- 2011-02-25 EP EP11713058.3A patent/EP2539366B1/en active Active
-
2013
- 2013-08-01 US US13/957,239 patent/US8859501B2/en active Active
-
2014
- 2014-08-28 US US14/472,036 patent/US8968734B2/en active Active
-
2015
- 2015-02-02 US US14/611,690 patent/US9084832B2/en active Active
-
2018
- 2018-02-05 CY CY20181100140T patent/CY1120014T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE038313T2 (hu) | Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban | |
| LT2282758T (lt) | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams | |
| IL243538B (en) | Artificial triterpenoids and methods for use in the treatment of disease | |
| ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
| ZA201209632B (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| AP2014007601A0 (en) | Novel purine derivatives and their use in the treatment of disease | |
| GB201105137D0 (en) | Therapeutic molecules for use in the suppression of Parkinson's disease | |
| LT2739615T (lt) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanonai ir jų panaudojimas kaip vaisto | |
| IL217293A0 (en) | NOVEL 1,2,3,4 - TETRAHYDROPYRIMIDO {1,2-a} PYRIMIDIN - 6 - ONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | |
| GB0918392D0 (en) | Diagnostic and therapeutic methods | |
| IL217209A0 (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
| PT2603238E (pt) | Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo | |
| EP2528939A4 (en) | RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH | |
| PT2670769T (pt) | R2r1/2 em diagnóstico e terapêutica | |
| PL2905588T3 (pl) | Bezszwowy korpus wagi i sposób wytwarzania | |
| EP2565184A4 (en) | THERAPEUTIC AGENT AND CONSERVATIVE AGENT AGAINST ALZHEIMER'S DISEASE | |
| ZA201306759B (en) | Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system | |
| PL2593129T3 (pl) | Nonapeptyd pat do stosowania w leczeniu choroby alzheimera | |
| HK1170538A (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
| Hume | Roger L’Estrange and the Making of Restoration Culture. | |
| AU2011900573A0 (en) | Alzheimer's Disease Biomarkers and Methods Using the Same | |
| HK1196617A (en) | Novel purine derivatives and their use in the treatment of disease | |
| GB0703450D0 (en) | Tropane derivatives, processes for their preparation and their use in medicine | |
| PL387749A1 (pl) | Nowe pochodne 4,5,6,7-tetrajodobenzimidazolu, sposób ich otrzymywania i zastosowanie medyczne | |
| GB201001170D0 (en) | Novel peptides and their use in therepy and diagnosis |